TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
PRINCIPAL ENDPOINT To value valganciclovir efficacy in advance treatment of CMV in patients
received allogenic transplant with a uniform treatment.
SECONDARY ENDPOINT To value valganciclovir security in advance treatment of CMV in in
patients received allogenic transplant with a uniform treatment.
The security will be valued by the % of patients that:
Will have negative CMV Neutropenia <1000 neutrophils/mm3 or <500 neutrophils/mm3 in the first
35 days of treatment - follow-up Renal toxicity in the first 35 days of treatment - follow-up
(defined by elevated creatinine >1mg/dL or twice the basal value) CMV illness during the
treatment or in the next 2 months Blood Antigenemia / PCR positive in the next 2months of
treatment
This dates Hill be compared with a patients control group treated with intravenous
valganciclovir